We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Money to Bern

17 October 2016 By Jeffrey Goldfarb

The U.S. senator sent shares of leukemia drug maker Ariad tumbling after he knocked its price increases. Statements by UK Prime Minister Theresa May and other officials also have affected a range of valuations. Investors will need to adjust to this direct kind of political risk.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)